Brought to you by 
CeNeS acquires products from Glaxo Wellcome
24 Apr 2003
Executive Summary
CeNeS Pharmaceuticals (CNS therapeutics) has acquired rights in the UK and Ireland to 3 marketed drugs--Diconal, Cyclimorph, and Valoid--from Glaxo Wellcome for £10mm ($15.3mm) in cash.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CeNeS acquires products from Glaxo Wellcome
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice